Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Dec;19(12):1537-1542.
doi: 10.1007/s12094-017-1700-8. Epub 2017 Jun 28.

Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 database

J Remon  1 , D Isla  2 , P Garrido  3 , J de Castro  4 , M Majem  5 , N Viñolas  6 , A Artal  7 , E Carcereny  8 , M R García-Campelo  9 , P Lianes  10 , M Provencio  11 , O Juan  12 , P Diz  13 , R Blanco  14 , R Lopez-Castro  15 , I Maestu  16 , C Vadell  17 , E Felip  18
Affiliations

Efficacy of tyrosine kinase inhibitors in EGFR-mutant lung cancer women in a real-world setting: the WORLD07 database

J Remon et al. Clin Transl Oncol. 2017 Dec.

Abstract

Background: The WORLD07 project is a female specific database to assess the characteristics of women with lung cancer.

Methods: WORLD07 database sets up in 2007, and prospectively stores clinical characteristics, treatment, outcome, and follow-up of lung cancer women. All women with epidermal growth factor receptor (EGFR) mutation non-small cell lung cancer (NSCLC) were selected for this analysis.

Results: From October 2007 to December 2012, a total of 1775 NSCLC women were recruited. EGFR mutation was identified in 34.4% of patients. Upfront EGFR tyrosine kinase inhibitor (TKI) reported a response rate of 60%, a median progression-free survival of 11.7 months, and median overall survival of 23.0 months. EGFR TKI, EGFR-mutation type, and smoking status did not impact in the outcome of treated women.

Conclusion: Prevalence of EGFR mutation in women with NSCLC is higher than overall population with NSCLC. Efficacy of EGFR TKI in this real-world setting is similar to that previously reported.

Keywords: Advanced; EGFR mutant; NSCLC; TKI; Women.

PubMed Disclaimer

References

    1. N Engl J Med. 2009 Sep 3;361(10):958-67 - PubMed
    1. Jpn J Clin Oncol. 2015 Jul;45(7):670-6 - PubMed
    1. J Natl Cancer Inst. 2000 Feb 2;92 (3):205-16 - PubMed
    1. Eur Respir J. 2016 Sep;48(3):889-902 - PubMed
    1. Future Oncol. 2015 ;11(8):1245-57 - PubMed

MeSH terms

LinkOut - more resources